Department of Gynecologic Surgery, Institut Gustave Roussy, Villejuif, France.
Ann Surg Oncol. 2011 Jan;18(1):40-8. doi: 10.1245/s10434-010-1293-8. Epub 2010 Aug 25.
To determine the prognosis and prognostic factors in a large series of mucinous borderline tumors of the ovary (MBOT).
A retrospective review of patients with MBOT treated or referred to our institution. Three inclusion criteria were defined: (1) centralized histological review by our expert pathologist, (2) exclusion of peritoneal pseudomyxoma and any synchronous malignant tumor in the abdominal cavity, and (3) available data on the management and outcomes of patients.
From 1997 to 2004, 97 patients fulfilled inclusion criteria (95 stage I and 2 stage II disease). Of these, 9 patients had endocervical-like subtypes, 8 patients had stromal microinvasion, and 24 had intraepithelial carcinoma. Radical and conservative surgeries were performed, respectively, in 28 and 69 patients. After a median follow-up of 48 months, 13 patients had developed 14 recurrences: 7 were borderline and 7 were invasive lesions. The probability of recurrence in the form of carcinoma 5 and 10 years after the diagnosis was, respectively, 9 and 13%. The only prognostic factor for recurrence attaining statistical significance was the use of a cystectomy (compared with other surgeries relative risk [RR] = 5.6; P = 0.003; compared with salpingo-oophorectomy RR = 5.5; P = 0.012).
In the present series of 97 MBOT, mainly early-stage disease and excluding peritoneal pseudomyxoma, the cumulative risk of recurrence in the form of invasive carcinoma at 10 years was 13%. MBOT do not appear to be such a "safe" disease. The only prognostic factor for recurrence was the use of a cystectomy, suggesting that a salpingo-oophorectomy should be preferred in cases of conservative treatment.
为了确定大型卵巢黏液性交界性肿瘤(MBOT)系列中患者的预后和预后因素。
对在我院接受治疗或转诊的 MBOT 患者进行回顾性研究。确定了三个纳入标准:(1)由我们的专家病理学家进行集中组织学审查;(2)排除腹膜假黏液瘤和腹腔内任何同步恶性肿瘤;(3)患者管理和结局数据可用。
1997 年至 2004 年,97 名患者符合纳入标准(95 例 I 期和 2 例 II 期疾病)。其中,9 例为宫颈样亚型,8 例为间质微浸润,24 例为上皮内癌。分别对 28 例和 69 例患者进行了根治性和保守性手术。中位随访 48 个月后,13 例患者发生 14 例复发:7 例为交界性,7 例为浸润性病变。诊断后 5 年和 10 年发生癌复发的概率分别为 9%和 13%。唯一具有统计学意义的复发预后因素是行囊肿切除术(与其他手术相比,相对风险[RR] = 5.6;P = 0.003;与输卵管卵巢切除术相比,RR = 5.5;P = 0.012)。
在本系列的 97 例 MBOT 中,主要为早期疾病,不包括腹膜假黏液瘤,10 年内以浸润性癌形式复发的累积风险为 13%。MBOT 似乎并非如此“安全”的疾病。唯一的复发预后因素是囊肿切除术的使用,这表明在保守治疗的情况下应首选输卵管卵巢切除术。